For the Inventor, By the Inventor

Enter assignee name

Culver City, CA, United States of America

Immunitybio, Inc.

USPTO Granted Patents = 52

CIPO Patents = 1

EPO Patents = 7

Trademarks = 17

Forward Citations = 70

Loading Chart...

Loading Chart...

42 inventors (with patents filed for the assignee):

Patrick Soon-Shiong (25 out of 443 patents)

Hans G Klingemann (20 out of 39 patents)

Laurent H Boissel (15 out of 28 patents)

4. Nicholas James Witchey (8 out of 143 patents)

5. Hing C Wong (6 out of 104 patents)

6. John Zachary Sanborn (6 out of 59 patents)

7. Barry J Simon (6 out of 16 patents)

8. Luna Witchey (6 out of 6 patents)

9. Rohit Duggal (5 out of 5 patents)

10. Kayvan R Niazi (5 out of 90 patents)

11. Shahrooz Rabizadeh (4 out of 82 patents)

12. Ranjeet Sinha (4 out of 4 patents)

13. Abhijit Dandapat (4 out of 5 patents)

14. Himani Chinnapen (4 out of 4 patents)

15. John H Lee (3 out of 12 patents)

Core Competencies:

Chimeric Antigen Receptor

Natural Killer Cells

Messenger RNA Production

Neoepitope Vaccine

Adenoviral Vectors

Tumoricidal Compositions

Digital Token Authentication

Immunotherapy Techniques

SARS-CoV-2 Vaccines

Mononuclear Cell Therapy

Genetically Modified Cells

Advanced Dendritic Cells

52 patents: Sort by Forward Citations

1. 12491201 - Maximizing T-cell memory and compositions and methods therefor (2025-12-09),

2. 12459981 - Primary NK CAR constructs and methods (2025-11-04),

3. 12456240 - Fiducial localization with sparse annotations (2025-10-28),

4. 12448638 - Enzyme based system for production of messenger RNA with increased transfection efficiency (2025-10-21),

5. 12435122 - Fc-epsilon CAR (2025-10-07),

6. 12409135 - Neoepitope vaccine delivery vehicle and methods of making the same (2025-09-09),

7. 12403178 - Use of CD33CAR modified high affinity NK cells (t-haNK) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on NK cell activity) (2025-09-02),

8. 12398186 - Multi-chain chimeric polypeptides and uses thereof (2025-08-26),

9. 12384852 - Genetically modified NK-92 cells having a safety switch (2025-08-12),

10. 12378300 - Elimination of CD19-positive lymphoid malignancies by CD19-car expressing NK cells (2025-08-05),

11. 12365874 - Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors (2025-07-22),

12. 12332986 - Content authentication and validation via multi-factor digital tokens, systems, and methods (2025-06-17),

13. 12290558 - SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogens (2025-05-06),

14. 12274748 - Adenoviral vector transduced apheresis product (2025-04-14),

15. 12272439 - Distributed ledger for medicament administration tracking (2025-04-08),

ImmunityBio, Inc. is a leading biotechnology company focused on developing next-generation immunotherapies to improve the treatment of cancer and infectious diseases. Combining expertise in immunology, bioinformatics, and nanotechnology, ImmunityBio aims to revolutionize the field of immunotherapy by developing innovative therapies that can activate and direct the immune system to combat diseases effectively. With a robust pipeline of novel drugs, ImmunityBio is dedicated to advancing the understanding and application of immunotherapy to provide better outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

52 Patents

#7 in Culver City, CA

#1,543 in California

#6,539 in US

#13,151 in the World

Culver City, CA, United States of America

Immunitybio, Inc.

Forward Citations = 70

42 inventors:

Patrick Soon-Shiong (25 out of 443 patents)

Hans G Klingemann (20 out of 39 patents)

Laurent H Boissel (15 out of 28 patents)

4. Nicholas James Witchey (8 out of 143 patents)

5. Hing C Wong (6 out of 104 patents)

Please report any incorrect information to support@idiyas.com

Loading…